JAK2 and precursor B-cell acute lymphoblastic leukemia: These synergistic effects were also observed in vivo, where the combination of CD19 CAR-T cells and CHZ868 prolonged the survival of JAK2 wild-type B-ALL model mice compared to CD19 CAR-T cell monotherapy.